Moore Capital Management’s Biogen BIIB Stock Holding History

Moore Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-90,000	Closed	-$23.3M	–	452
2023 Q4	$23.3M	Buy	90,000 +30,000	+50%	+$7.37M	0.4%	43
2023 Q3	$15.4M	Buy	+60,000	New	+$16M	0.29%	68
2023 Q2	–	Sell	-1,500	Closed	-$417K	–	524
2023 Q1	$417K	Buy	+1,500	New	+$415K	0.01%	328
2022 Q4	–	Sell	-17,995	Closed	-$4.8M	–	558
2022 Q3	$4.8M	Sell	17,995 -10,684	-37%	-$2.27M	0.11%	202
2022 Q2	$5.85M	Buy	+28,679	New	+$5.86M	0.15%	147
2021 Q4	–	Sell	-20,206	Closed	-$5.72M	–	748
2021 Q3	$5.72M	Sell	20,206 -58,952	-74%	-$19.3M	0.09%	225
2021 Q2	$27.4M	Buy	+79,158	New	+$24M	0.39%	56
2020 Q1	–	Sell	-9,924	Closed	-$2.94M	–	173
2019 Q4	$2.94M	Buy	+9,924	New	+$2.75M	0.1%	174
2019 Q1	–	Sell	-33,792	Closed	-$10.2M	–	295
2018 Q4	$10.2M	Buy	+33,792	New	+$10.8M	0.4%	50
2014 Q3	–	Sell	-32,500	Closed	-$10.2M	–	407
2014 Q2	$10.2M	Buy	+32,500	New	+$9.78M	0.25%	103
2013 Q4	–	Sell	-10,000	Closed	-$2.41M	–	373
2013 Q3	$2.41M	Buy	10,000 +5,000	+100%	+$1.12M	0.05%	229
2013 Q2	$1.08M	Buy	+5,000	New	+$1.07M	0.03%	244

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moore Capital Management's BIIB Position: Q1 2024 in Review

Moore Capital Management sold out of Biogen (BIIB) in Q1 2024, closing a stake of 90,000 shares — an estimated $23.3M sold.

Moore Capital Management first reported a position in BIIB in Q2 2013 and held it in 12 quarters. The position peaked at $27.4M in Q2 2021. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Moore Capital Management reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Moore Capital Management sold 90,000 Biogen shares in Q1 2024, an estimated $23.3M.
Moore Capital Management first reported a position in Biogen in Q2 2013 and held it in 12 quarters.
Moore Capital Management's Biogen position peaked at $27.4M in Q2 2021.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Moore Capital Management's 13F filing for Q1 2024, filed 15 May 2024.